E
Sonoma Pharmaceuticals, Inc.
SNOA
$2.77
$0.7839.20%
E
Sell
10/24/2024Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 10/24/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 1.69 to 1.62.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 10/24/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 1.69 to 1.62.
D
Sell
7/25/2024Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 7/25/2024 due to a noticeable increase in the growth index, solvency index and volatility index. Operating cash flow increased 113.77% from -$1.1M to $152, earnings per share increased from -$0.08 to -$0.0696, and total revenue increased 9.59% from $3.14M to $3.44M.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 7/25/2024 due to a noticeable increase in the growth index, solvency index and volatility index. Operating cash flow increased 113.77% from -$1.1M to $152, earnings per share increased from -$0.08 to -$0.0696, and total revenue increased 9.59% from $3.14M to $3.44M.
E
Sell
3/14/2023Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell
2/15/2023Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 2/15/2023 due to an increase in the growth index. Operating cash flow increased 80.98% from -$1.83M to -$348.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 2/15/2023 due to an increase in the growth index. Operating cash flow increased 80.98% from -$1.83M to -$348.
E
Sell
2/8/2023Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
11/21/2022Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D- from D on 11/21/2022 due to a major decline in the growth index, total return index and solvency index. Operating cash flow declined 19.37% from -$1.53M to -$1.83M, total revenue declined 16.37% from $3.98M to $3.33M, and earnings per share declined from -$0.29 to -$0.33.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D- from D on 11/21/2022 due to a major decline in the growth index, total return index and solvency index. Operating cash flow declined 19.37% from -$1.53M to -$1.83M, total revenue declined 16.37% from $3.98M to $3.33M, and earnings per share declined from -$0.29 to -$0.33.
D
Sell
8/15/2022Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D from D- on 8/15/2022 due to a substantial increase in the growth index, total return index and volatility index. Total revenue increased 73.32% from $2.3M to $3.98M, EBIT increased 72.06% from -$3.06M to -$855, and earnings per share increased from -$0.956 to -$0.29.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D from D- on 8/15/2022 due to a substantial increase in the growth index, total return index and volatility index. Total revenue increased 73.32% from $2.3M to $3.98M, EBIT increased 72.06% from -$3.06M to -$855, and earnings per share increased from -$0.956 to -$0.29.
D
Sell
5/16/2022Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 5/1/2022 due to a decline in the total return index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 5/1/2022 due to a decline in the total return index.
D
Sell
2/16/2022Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D- from D on 2/16/2022 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0427 to -$0.31, and total revenue declined 22.49% from $3.74M to $2.9M.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D- from D on 2/16/2022 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0427 to -$0.31, and total revenue declined 22.49% from $3.74M to $2.9M.
D
Sell
11/16/2021Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D from D- on 11/16/2021 due to an increase in the solvency index. The quick ratio increased from 1.15 to 2.95, and debt to equity declined from 0.42 to 0.09.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D from D- on 11/16/2021 due to an increase in the solvency index. The quick ratio increased from 1.15 to 2.95, and debt to equity declined from 0.42 to 0.09.
D
Sell
11/8/2021Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
9/3/2021Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D from D+ on 9/3/2021 due to a decline in the volatility index and total return index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D from D+ on 9/3/2021 due to a decline in the volatility index and total return index.
D
Sell
8/19/2021Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D+ from D on 8/19/2021 due to a large increase in the total return index, volatility index and growth index. Total revenue increased 70.79% from $2.16M to $3.68M, earnings per share increased from -$1.7554 to -$0.5246, and EBIT increased 67.87% from -$2.81M to -$904.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D+ from D on 8/19/2021 due to a large increase in the total return index, volatility index and growth index. Total revenue increased 70.79% from $2.16M to $3.68M, earnings per share increased from -$1.7554 to -$0.5246, and EBIT increased 67.87% from -$2.81M to -$904.
D
Sell
5/1/2020Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D from E+ on 5/1/2020 due to an increase in the volatility index, total return index and growth index.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D from E+ on 5/1/2020 due to an increase in the volatility index, total return index and growth index.
E
Sell
3/4/2020Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 3/4/2020 due to a decline in the volatility index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 3/4/2020 due to a decline in the volatility index.
D
Sell
2/18/2020Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 2/18/2020 due to a major increase in the growth index, volatility index and efficiency index. Earnings per share increased from -$0.9134 to -$0.7227, EBIT increased 18.3% from -$1.2M to -$982, and net income increased 9.89% from -$1.2M to -$1.08M.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 2/18/2020 due to a major increase in the growth index, volatility index and efficiency index. Earnings per share increased from -$0.9134 to -$0.7227, EBIT increased 18.3% from -$1.2M to -$982, and net income increased 9.89% from -$1.2M to -$1.08M.
E
Sell
2/13/2020Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 2/13/2020 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from $0.54 to -$0.9134, and operating cash flow declined 221.68% from $738 to -$898.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 2/13/2020 due to a decline in the growth index, volatility index and total return index. Earnings per share declined from $0.54 to -$0.9134, and operating cash flow declined 221.68% from $738 to -$898.
D
Sell
7/5/2019Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 7/5/2019 due to an increase in the valuation index and volatility index.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D- from E+ on 7/5/2019 due to an increase in the valuation index and volatility index.
E
Sell
6/19/2019Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 6/19/2019 due to a noticeable decline in the total return index, volatility index and valuation index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to E+ from D- on 6/19/2019 due to a noticeable decline in the total return index, volatility index and valuation index.
D
Sell
2/23/2018Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D- from D+ on 2/23/2018 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 12.01% from -$2.86M to -$3.2M, total capital declined 11.91% from $16.61M to $14.63M, and net income declined 11.05% from -$2.87M to -$3.19M.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D- from D+ on 2/23/2018 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 12.01% from -$2.86M to -$3.2M, total capital declined 11.91% from $16.61M to $14.63M, and net income declined 11.05% from -$2.87M to -$3.19M.
D
Sell
2/20/2018Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D+ from D on 2/20/2018 due to an increase in the volatility index, total return index and valuation index.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D+ from D on 2/20/2018 due to an increase in the volatility index, total return index and valuation index.
D
Sell
2/5/2018Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D from D+ on 2/5/2018 due to a decline in the total return index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D from D+ on 2/5/2018 due to a decline in the total return index.
D
Sell
1/9/2018Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D+ from D on 1/9/2018 due to a major increase in the growth index and efficiency index. Operating cash flow increased 43.91% from -$4.63M to -$2.6M, earnings per share increased from -$0.817 to -$0.6654, and net income increased 18.19% from -$3.51M to -$2.87M.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D+ from D on 1/9/2018 due to a major increase in the growth index and efficiency index. Operating cash flow increased 43.91% from -$4.63M to -$2.6M, earnings per share increased from -$0.817 to -$0.6654, and net income increased 18.19% from -$3.51M to -$2.87M.
D
Sell
9/13/2017Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D from D+ on 9/13/2017 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 71.95% from -$2.7M to -$4.63M, earnings per share declined from -$0.5804 to -$0.817, and EBIT declined 16.17% from -$2.91M to -$3.38M.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D from D+ on 9/13/2017 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 71.95% from -$2.7M to -$4.63M, earnings per share declined from -$0.5804 to -$0.817, and EBIT declined 16.17% from -$2.91M to -$3.38M.
D
Sell
8/10/2017Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D+ from C- on 8/10/2017 due to a decline in the total return index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D+ from C- on 8/10/2017 due to a decline in the total return index.
C
Hold
7/26/2017Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to C- from D+ on 7/26/2017 due to an increase in the total return index and volatility index.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to C- from D+ on 7/26/2017 due to an increase in the total return index and volatility index.
D
Sell
6/30/2017Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D+ from C- on 6/30/2017 due to a major decline in the growth index, efficiency index and solvency index. Earnings per share declined from $3.8378 to -$0.5804, net income declined 115.01% from $16.23M to -$2.44M, and total capital declined 4.72% from $22.92M to $21.84M.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to D+ from C- on 6/30/2017 due to a major decline in the growth index, efficiency index and solvency index. Earnings per share declined from $3.8378 to -$0.5804, net income declined 115.01% from $16.23M to -$2.44M, and total capital declined 4.72% from $22.92M to $21.84M.
C
Hold
6/27/2017Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to C- from C on 6/27/2017 due to a noticeable decline in the total return index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to C- from C on 6/27/2017 due to a noticeable decline in the total return index.
C
Hold
6/12/2017Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to C from C- on 6/12/2017 due to an increase in the total return index and volatility index.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to C from C- on 6/12/2017 due to an increase in the total return index and volatility index.
C
Hold
5/26/2017Downgrade
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to C- from C on 5/26/2017 due to a decline in the total return index.
Sonoma Pharmaceuticals, Inc. (SNOA) was downgraded to C- from C on 5/26/2017 due to a decline in the total return index.
C
Hold
3/29/2017Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to C from C- on 3/29/2017 due to a large increase in the total return index and volatility index.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to C from C- on 3/29/2017 due to a large increase in the total return index and volatility index.
C
Hold
3/9/2017Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to C- from D+ on 3/9/2017 due to a large increase in the total return index, volatility index and growth index.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to C- from D+ on 3/9/2017 due to a large increase in the total return index, volatility index and growth index.
D
Sell
2/21/2017Upgraded
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D+ from D- on 2/21/2017 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 932.63% from -$1.95M to $16.23M, earnings per share increased from -$0.4638 to $3.8378, and total capital increased 274.74% from $6.12M to $22.92M.
Sonoma Pharmaceuticals, Inc. (SNOA) was upgraded to D+ from D- on 2/21/2017 due to a significant increase in the valuation index, efficiency index and growth index. Net income increased 932.63% from -$1.95M to $16.23M, earnings per share increased from -$0.4638 to $3.8378, and total capital increased 274.74% from $6.12M to $22.92M.
D
Sell
7/11/2016Upgraded
Oculus Innovative Sciences, Inc. (OCLS) was upgraded to D- from E+ on 7/11/2016 due to a significant increase in the solvency index, growth index and valuation index.
Oculus Innovative Sciences, Inc. (OCLS) was upgraded to D- from E+ on 7/11/2016 due to a significant increase in the solvency index, growth index and valuation index.
E
Sell
6/24/2016Downgrade
Oculus Innovative Sciences, Inc. (OCLS) was downgraded to E+ from D- on 6/24/2016 due to a significant decline in the solvency index, valuation index and growth index.
Oculus Innovative Sciences, Inc. (OCLS) was downgraded to E+ from D- on 6/24/2016 due to a significant decline in the solvency index, valuation index and growth index.
D
Sell
3/11/2016Downgrade
Oculus Innovative Sciences, Inc. (OCLS) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and growth index. Earnings per share declined from -$0.1084 to -$0.1912, EBIT declined 68.14% from -$1.86M to -$3.12M, and operating cash flow declined 53.95% from -$1.75M to -$2.69M.
Oculus Innovative Sciences, Inc. (OCLS) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, total return index and growth index. Earnings per share declined from -$0.1084 to -$0.1912, EBIT declined 68.14% from -$1.86M to -$3.12M, and operating cash flow declined 53.95% from -$1.75M to -$2.69M.
D
Sell
6/19/2015Downgrade
Oculus Innovative Sciences, Inc. (OCLS) was downgraded to D from C- on 6/19/2015 due to a significant decline in the valuation index and efficiency index. Net income declined 74.62% from -$5.91M to -$1.5M.
Oculus Innovative Sciences, Inc. (OCLS) was downgraded to D from C- on 6/19/2015 due to a significant decline in the valuation index and efficiency index. Net income declined 74.62% from -$5.91M to -$1.5M.
C
Hold
2/17/2015Downgrade
Oculus Innovative Sciences, Inc. (OCLS) was downgraded to C- from C on 2/17/2015 due to a noticeable decline in the efficiency index, growth index and solvency index. Total capital declined 41.44% from $13.38M to $7.83M, operating cash flow declined 36.56% from -$1.66M to -$1.06M, and the quick ratio declined from 1.28 to 1.04.
Oculus Innovative Sciences, Inc. (OCLS) was downgraded to C- from C on 2/17/2015 due to a noticeable decline in the efficiency index, growth index and solvency index. Total capital declined 41.44% from $13.38M to $7.83M, operating cash flow declined 36.56% from -$1.66M to -$1.06M, and the quick ratio declined from 1.28 to 1.04.
C
Hold
8/20/2014Upgraded
Oculus Innovative Sciences, Inc. (OCLS) was upgraded to C from C- on 8/20/2014 due to a noticeable increase in the efficiency index and valuation index. Total capital increased 10.3% from $12.21M to $13.47M.
Oculus Innovative Sciences, Inc. (OCLS) was upgraded to C from C- on 8/20/2014 due to a noticeable increase in the efficiency index and valuation index. Total capital increased 10.3% from $12.21M to $13.47M.
C
Hold
7/7/2014Upgraded
Oculus Innovative Sciences, Inc. (OCLS) was upgraded to C- from D on 7/7/2014 due to a significant increase in the valuation index, efficiency index and solvency index. Total capital increased 254.32% from $3.45M to $12.21M.
Oculus Innovative Sciences, Inc. (OCLS) was upgraded to C- from D on 7/7/2014 due to a significant increase in the valuation index, efficiency index and solvency index. Total capital increased 254.32% from $3.45M to $12.21M.
NASDAQ
03/10/2025 2:24PM Eastern
Quotes delayed
